Pembrolizumab und Cetuximab als therapeutische Optionen für adenoidzystische Karzinome des Kopf-Hals-Bereiches

Ioannis Michaelides; Sandra Fest; Michael Berszin; Susanne Wiegand; Christopher Bohr; Julian Künzel; Andreas Dietz; Markus Pirlich; Gunnar Wichmann

doi:10.1055/a-1830-8298

Laryngo-Rhino-Otologie, Table of Contents

Laryngorhinootologie 2022; 101(09): 736-740
DOI: 10.1055/a-1830-8298

Originalarbeit

Pembrolizumab und Cetuximab als therapeutische Optionen für adenoidzystische Karzinome des Kopf-Hals-Bereiches

Pembrolizumab and Cetuximab as therapeutic options for ACC in head and neck

Ioannis Michaelides∗

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

²Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland

,

Sandra Fest∗

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

,

Michael Berszin

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

,

Susanne Wiegand

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

,

Christopher Bohr

²Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland

,

Julian Künzel

²Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde, Universitätsklinikum Regensburg, Regensburg, Deutschland

,

Andreas Dietz

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

,

Markus Pirlich‡

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

,

Gunnar Wichmann‡

¹Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Leipzig, Leipzig, Deutschland

› Author Affiliations

Abstract

Schlüsselwörter

Adenoid-zystisches Karzinom - Kopf-Hals-Tumore - ex vivo - FLAVINO-Assay - Chemoresponse-Test - Pembrolizumab - Cetuximab - Immun-Checkpoint-Blockade - PD-1/PD-L1 Signalweg

Keywords

Adenoid-cystic carcinoma (ACC) - head and neck cancer - FLAVINO assay - chemoresponse test - pembrolizumab - cetuximab

Full Text

References

References
1 Bilroth T. Germany: G Riemer; 1856. The Cylindroma Studies on the development of the blood vessels along with observations from the Royal University Surgical Clinic Berlin.55–69.
2 Bubendorf L, Feichter GE, Obermann EC. et al. Pathologie – Zytopathologie.
3 Böcker W, Denk H, Heitz PU. et al. Lehrbuch Pathologie. Elsevier Health Sciences. 2019
4 Martinez-Rodriguez N, Leco-Berrocal I, Rubio-Alonso L. et al. Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: a meta-analytic study. Med Oral Patol Oral Cir Bucal 2011; 16 (07) e884-e889
5 Miglianico L, Eschwege F, Marandas P. et al. Cervico-facial adenoid cystic carcinoma: study of 102 cases. Influence of radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13 (05) 673-678
6 Hosni A, Huang SH, Goldstein D. et al. Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. Oral Oncol 2016; 54: 75-80
7 Licitra L, Cavina R, Grandi C. et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol 1996; 07 (06) 640-642
8 Hill M, Constenla D, Ahern R. et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 1997; 33 (04) 275-278
9 Suzuki S, Dobashi Y, Minato H. et al. EGFR and HER2–Akt–mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Archiv 2012; 461 (03) 271-282
10 Sridharan V, Gjini E, Liao X. et al. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunol Res 2016; 04 (08) 679-687
11 Hitre E, Budai B, Takacsi-Nagy Z. et al. Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 2013; 109 (05) 1117-1122
12 Mahmood U, Bang A, Chen YH. et al. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys 2020;
13 Moskaluk CA. Adenoid cystic carcinoma: clinical and molecular features. Head Neck Pathol 2013; 07 (01) 17-22
14 Azumi N, Battifora H. The cellular composition of adenoid cystic carcinoma. An immunohistochemical study 1987; 60 (07) 1589-1598
15 Caselitz J, Schulze I, Seifert G. Adenoid cystic carcinoma of the salivary glands: an immunohistochemical study. J Oral Pathol 1986; 15 (06) 308-318
16 Bell D, Roberts D, Kies M. et al. Cell type-dependent biomarker expression in adenoid cystic carcinoma. Cancer 2010; 116 (24) 5749-5756
17 Da Cruz Perez DE, De Abreu Alves F, Nobuko Nishimoto I. et al. Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncology 2006; 42 (02) 139-146
18 Dillon PM, Chakraborty S, Moskaluk CA. et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head & Neck 2016; 38 (04) 620-627
19 Amit M, Binenbaum Y, Trejo-Leider L. et al. International collaborative validation of intraneural invasion as a prognostic marker in adenoid cystic carcinoma of the head and neck. Head & Neck 2015; 37 (07) 1038-1045
20 Dietz A, Boehm A, Horn IS. et al. Assay-based response evaluation in head and neck oncology: requirements for better decision making. Eur Arch Otorhinolaryngol 2010; 267 (04) 483-494
21 Chae YK, Chung SY, Davis AA. et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget 2015; 06 (35) 37117-37134
22 Jagielska B, Sarnowska E, Sarnowski T. et al. Contemporary diagnostic and therapeutic possibilities in patients with adenoid cystic carcinoma of the head and neck. Oncology in Clinical Practice 2020; 16 (01) 1-8
23 Papaspyrou G, Hoch S, Rinaldo A. et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 33 (06) 905-911
24 Lagha A, Chraiet N, Ayadi M. et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head & Neck Oncology 2012; 04 (01) 19
25 Subramaniam T, Lennon P, O’Neill JP. Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck. Irish Journal of Medical Science (1971 -) 2015; 184 (03) 583-590
26 Gessner K, Wichmann G, Boehm A. et al. Therapeutic options for treatment of Merkel cell carcinoma. Eur Arch Otorhinolaryngol 2011; 268 (03) 443-448
27 Liu NN, Zhang SL, Chen W. The cross-contaminated cell lines of adenoid cystic carcinoma: A crucial concern. Translational Surgery 2017; 02 (01) 10-13